<DOC>
	<DOCNO>NCT00089986</DOCNO>
	<brief_summary>The primary objective estimate size GR270773 treatment effect 28-day all-cause mortality two dos GR270773 versus placebo adult subject suspect confirmed Gram-negative severe sepsis . GR270773 administer three-day continuous intravenous infusion .</brief_summary>
	<brief_title>GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>Inclusion criterion : Receiving parenteral antibiotic therapy suspect confirmed Gramnegative infection . Have least one new hypoperfusion abnormality least one new onset organ failure result current septic episode . Must available able receive first dose study medication 12 hour confirmation new hypoperfusion abnormality new onset organ failure within 36 hour initiation new parenteral antibacterial therapy suspect confirmed Gramnegative infection believe responsible episode sepsis . Exclusion criterion : Subject unlikely remain hospital minimum three day ( 72 hour ) follow enrollment . Subject neutropenia ( e.g. , subject recently receive cytotoxic chemotherapy absolute neutrophil count &lt; 500/mcL expect decline &lt; 500/mcL next 3 day ) . Subject know active hemolytic disease , immune hemolytic anemia , hemoglobinopathy ( sickle cell anemia thalassemia major ) . Subject know bone marrow disorder inadequate red cell production ( eg , aplastic anemia , myelodysplasia ) . Subject increase risk complication GR270773related hemolysis due inability increase cardiac function sufficiently meet demand oxygen delivery . Subject baseline hemoglobin ( measured adequate volume resuscitation ) &lt; 9.0 g/dL ( 5.59 mmol/L ) . Subject currently treat XIGRIS ( Drotrecogin alfa ( activate ) ) use consider imminent ( ie. , decision treat XIGRIS make ) . Subject history allergic reaction egg ( egg product ) , soybean , INTRALIPID , component GR270773 . Subject designate 'not full support resuscitate ' ( DNR ) , equivalent status prohibits use life support intervention ( e.g. , mechanical ventilation , dialysis/hemofiltration , others ) thereby limit treatment option available . Note : Subjects advance directive prohibit chest compression ( CPR ) eligible study . Subject preexist severe liver disease cirrhosis , primary biliary cirrhosis know preexist ChildPugh class B C liver dysfunction . Subject moribund ( state death perceive imminent ) life expectancy le 3 month due underlying disease . Subject currently receive one follow prohibit concomitant medication ; parenteral nutrition supplement contain lipid emulsion ( e.g. , INTRALIPID ) , amphotericin , liposomal amphotericin , amphotericin B lipid complex .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>septic shock</keyword>
	<keyword>phospholipid emulsion</keyword>
	<keyword>Gram-negative infection</keyword>
	<keyword>severe sepsis</keyword>
</DOC>